By NewsDesk @bactiman63
In a follow-up on the chikungunya outbreak in Chad, health authorities have reported 34,445 cases of Chikungunya, including one death since August 14.
Cases have been confirmed in health districts of Abéché (Ouaddai Province), Biltine (Wadi Fira Province), and d’Abdi, Gozbeida (Sila Province).
More than three quarters of patients develop severe fevers, headaches, excruciating and disabling joint pain; a third of these patients developed pruritic maculopapular rashes.
The World Health Organization says chikungunya is an arboviral disease transmitted to humans by the bites of infected Aedes mosquitoes. The disease is characterized by an abrupt onset of fever frequently accompanied by joint pain and inflammation which is often very debilitating and may last for several months, or even years. Fatalities associated with infection can occur but are typically rare and most reported in older adults with underlying medical conditions or perinatally-infected infants. Some patients might have a relapse of rheumatologic symptoms (e.g. polyarthralgia, polyarthritis, and tenosynovitis) in the months following acute illness.
There is no specific antiviral treatment or commercially available vaccine for chikungunya.
- CDC COVID-19 update: Potential for airborne spread added to website
- Canada: Salmonella outbreak linked to pig ear dog treats
- Philippines COVID-19 update: 2,291 new cases Monday, WHO donates PPE, medical supplies
- SARS-CoV-2: A broad range of mammals could be susceptible to virus, according to study
- Michigan: Eastern equine encephalitis death reported in Montcalm County
- COVID-19: Best Ways to Strengthen Your Immune System
- Sudan reports another polio case, Vaccination campaign planned for 8.6 million children